Navigation Links
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
Date:11/24/2008

-Phase I/II studies summarized-

BELLEVILLE, ON, Nov. 24 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data about its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) - trademarked Urocidin - to an international audience of urologists at the 2008 Societe Internationale d'Urologie (SIU) Congress in Santiago, Chile on Saturday.

The presentation, entitled, "Patients Age in Bladder Cancer Immunotherapy Response and Adverse Events: MCC Experience", was presented by Dr. Francois Charette, Senior Vice-President and Chief Medical Officer of Bioniche Life Sciences Inc.

In his presentation, Dr. Charette summarized the results of Phase I/II clinical studies with MCC, which involved 130 patients with Carcinoma in situ (CIS) high grade bladder cancer, with or without papillary lesions. The majority of these patients (62%) had been previously treated with bacillus Calmette- Guerin (BCG). The average age of the study participants was 73 years. The SIU presentation concluded that MCC has an excellent safety profile in older patients. Furthermore, the complete response rate, a measure of efficacy for bladder cancer, was similar between older and younger patients.

The SIU is the world's only truly international professional organization serving the global community of urologists. Founded in Paris in 1907, the SIU Central Office now serves its members from Montreal, Quebec, Canada. SIU members represent the full spectrum of clinicians and investigators from all subspecialties that come together to diagnose, treat and support patients with urological disease.

Urocidin is currently undergoing clinical testing in a pivotal Phase III clinical trial. In this trial, patients with non-muscle-invasive bladder cancer whose cancer is specifically refractory (unresponsive) to BCG therapy will receive Urocidin in an open label study. Thirty-one urology centres in North America are participating and enrolment is expected to be completed in the first quarter of calendar 2009.

BCG, the standard of care for non-muscle-invasive bladder cancer, has limited efficacy, especially as second-line therapy. It is associated with a number of treatment-limiting side effects that include the potential for both local (bladder) and systemic mycobacterial infections. Elderly patients do not seem to respond as well to BCG treatment and are more prone to adverse events.

The refractory to BCG indication was given Fast Track designation by the U.S. Food and Drug Administration (FDA) in April of 2006. The Company commenced this trial in November, 2006. An investigators' meeting was held in April, 2007 and the 31st site was validated in June, 2008.

Bioniche is planning to conduct a second registration trial which will directly compare the efficacy and safety of MCC with BCG in the treatment of non-muscle-invasive bladder cancer. In September, 2007, the Company announced that an agreement has been reached with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure on the design of the trial, including its endpoints, data analysis and conduct. It provides assurance that, if the trial endpoints are met, they will serve as the basis for product approval under a Biologics Licensing Application (BLA). An SPA gives a clear pathway to registration of MCC when the trial endpoints are achieved. This study received Fast Track designation by the FDA earlier this year.

About MCC

MCC is a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. It is formulated as Urocidin(TM) for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into contact with immune system cells and bladder cancer cells. MCC is undergoing preclinical evaluation as a treatment for peritoneal carcinomatosis associated with colon and ovarian cancer.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Reports Fiscal 2009 First Quarter
2. Bioniche Allows Conversion of Portion of Revolving Credit Facility
3. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
4. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
5. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
6. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
7. Bioniche Presents Pre-Clinical Research at Two International Conferences
8. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
9. Bioniche Reports Fiscal 2008 Third Quarter
10. Bioniche Appoints U.S. President of Food Safety
11. Bioniche Reports the Passing of its Board Chair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: